NASDAQ:MNOV
MediciNova Stock News
$1.42
-0.0100 (-0.699%)
At Close: May 17, 2024
LA JOLLA, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (
Medicinova stock up on European patent award
10:15am, Wednesday, 16'th Aug 2023
Medicinova Inc (NASDAQ:MNOV) stock started Wednesday on the front foot boosted by a patent award in Europe. The European Patent Office has given protection to the company's asset MN-001 (tipelukast) f
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
07:00pm, Tuesday, 15'th Aug 2023
LA JOLLA, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (
LA JOLLA, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
07:00pm, Thursday, 15'th Sep 2022
LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (C
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
10:30am, Wednesday, 27'th Jul 2022 GlobeNewswire Inc.
LA JOLLA, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (
MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
10:30am, Tuesday, 26'th Jul 2022 GlobeNewswire Inc.
LA JOLLA, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange
MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)
11:00pm, Thursday, 21'st Jul 2022 GlobeNewswire Inc.
LA JOLLA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange
MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
11:00pm, Wednesday, 29'th Jun 2022 GlobeNewswire Inc.
LA JOLLA, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange
MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan
11:00pm, Wednesday, 22'nd Jun 2022 GlobeNewswire Inc.
LA JOLLA, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange
MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
10:30am, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
LA JOLLA, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange
MediciNova Posts Promising Data From COVID-19 Treatment Candidate
09:15am, Wednesday, 08'th Jun 2022
MediciNova Inc (NASDAQ: MNOV) says the Phase 2 trial of MN-166 (ibudilast) in hospitalized COVID-19 patients demonstrated significant improvements compared to placebo for all four clinical endpoint
MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference
11:00pm, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
LA JOLLA, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange
MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research
11:00pm, Wednesday, 20'th Apr 2022 GlobeNewswire Inc.
LA JOLLA, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
03:00am, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
LA JOLLA, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange
